Ultrasound therapy developer Theraclion is directing attention to three recent studies involving its Echopulse high-intensity focused ultrasound (HIFU) technology.
In a paper published in the September issue of the International Journal of Hyperthermia, researchers from Guy's and St. Thomas University Hospital in London found that Echopulse was effective in the circumferential treatment of fibroadenoma.
Another study presented at the annual meeting of the European Thyroid Association found that ultrasound-guided ablation with Echopulse effectively reduced thyroid nodule volume. The researchers from the University Hospital of Endocrinology of Sofia, Bulgaria, also found the treatment, unlike surgical approaches, only has transient influence on thyroid function.
The Bulgarian researchers also presented results from a prospective dual-arm study at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2016 Congress in Barcelona, Spain. They reported that one and two consecutive HIFU treatments with Echopulse produce comparable effects and the method is safe and well-tolerated by patients, Theraclion said.
